BCRX - バイオクリスト・ファ―マシュ―ティカルズ （BioCryst Pharmaceuticals Inc.） バイオクリスト・ファ―マシュ―ティカルズBCRXのチャート
BCRXの企業情報
| symbol | BCRx |
|---|---|
| 会社名 | BioCryst Pharmaceuticals Inc （バイオクリスト・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 バイオクリスト・ファーマシューティカルズ（BioCryst Pharmaceuticals Inc.）はバイオテクノロジー企業である。病気の病因に関与する酵素をブロックする小分子薬の設計、最適化と開発を行う。同社は希少疾患の治療に集中する。同社はX線結晶学、分子構造のコンピュータモデリングと化学技術を利用して細胞生物学を制御する酵素の活性部位特性と三次元的な分子構造の解明に集中する。同社の薬剤候補はRAPIVAB、RAPIACTA、ALPIVAB、PERAMIFLU、Avoralstat、BCX7353、他の第二世代遺伝性血管浮腫（HAE）化合物、GalidesivirとForodesineなどを含む。同社の製品RAPIVABはペラミビルを含む。ALPIVABは静脈内ノイラミニダーゼ阻害剤である。Galidesivirは出血熱ウイルスの治療に向けの広域抗ウイルス（BSAV）研究プログラムである。Forodesineはがん治療薬としてMundipharmaによる開発されたプリンヌクレオシドホスホリラーゼ（PNP）阻害剤である。 バイオクリスト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。疾患の発症を引き起こす酵素を阻害する薬剤の開発に従事。インフルエンザ患者の治療薬ペラミビル、痛風治療薬ウロデシン、血液学的悪性腫瘍の治療薬フォロデシン、遺伝性血管性浮腫（HAE）の治療薬BCX4161などの開発を行う。またエボラウィルスの治療用抗ウィルスの研究を手掛ける。 BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. |
| 本社所在地 | 4505 Emperor Blvd. Suite 200 Durham NC 27703 USA |
| 代表者氏名 | Robert A. Ingram ロバートA.イングラム |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-859-1302 |
| 設立年月日 | 1986年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1994年 |
| 従業員数 | 85人 |
| url | www.biocryst.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bcrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -70.93800 |
| 終値（lastsale） | 6.79 |
| 時価総額（marketcap） | 744144753.8 |
| 時価総額 | 時価総額（百万ドル） 745.24070 |
| 売上高 | 売上高（百万ドル） 29.12000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 716.19070 |
| 当期純利益 | 当期純利益（百万ドル） -78.90000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioCryst Pharmaceuticals Inc. revenues increased 31% to $16.5M. Net loss increased 42% to $44.2M. Revenues reflect Collaborative and other research and dev increase from $5.7M to $12.7M. Higher net loss reflects General_Administrative increase from $5.9M to $17.1M (expense) Research and development increase of 21% to $39.5M (expense). |
BCRXのテクニカル分析
BCRXのニュース
Traders cant mares this Stock: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Outlook Therapeutics, Inc. (NASDAQ:OTLK) 2021/08/01 21:18:15 Stock Equity
BioCryst Pharmaceuticals, Inc. (BCRX) with the stream of -3.82% also noticed, India Outlook Therapeutics, Inc. (OTLK) encountered a rapid change of -6.22% in the last hour of trading session. BioCryst The post Traders cant mares this Stock: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Outlook Therapeutics, Inc. (NASDAQ:OTLK) appeared first on Stocks Equity .
BioCryst Appoints Vincent Milano to Board of Directors 2021/07/28 11:00:00 Intrado Digital Media
RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.
Global Hereditary Angioedema Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pharming Group NV, iBio Inc., Takeda, CSL Limited, Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. 2021/07/23 21:03:54 Jumbo News
The report on Global Hereditary Angioedema Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
BioCryst to Report Second Quarter 2021 Financial Results on August 5 2021/07/22 11:00:00 Intrado Digital Media
RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Thursday, August 5, 2021.
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price 2021/07/22 03:04:00 Seeking Alpha
Analyzing Analysts Recommendations: AstraZeneca PLC (NASDAQ:AZN), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 2021/07/11 21:13:26 Stock Equity
AstraZeneca PLC (AZN) with the stream of 0.62% also noticed, India BioCryst Pharmaceuticals, Inc. (BCRX) encountered a rapid change of 0.68% in the last hour of Fridays trading session. AstraZeneca The post Analyzing Analysts Recommendations: AstraZeneca PLC (NASDAQ:AZN), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) appeared first on Stocks Equity .
Have an attention on: Canaan Inc. (NASDAQ:CAN), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 2021/07/07 22:14:53 Stock Equity
Canaan Inc. (NASDAQ:CAN) with the stream of -6.73% also noticed, India BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) encountered a rapid change of -0.68% in the last hour of Wednesdays trading session. Canaan The post Have an attention on: Canaan Inc. (NASDAQ:CAN), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) appeared first on Stocks Equity .
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher? 2021/07/03 04:54:39 Nasdaq
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher? Nasdaq
ORLADEYO (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021/07/01 20:15:00 Wallstreet:Online
RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress from July 10-12, 2021. Durable Reduction in Hereditary Angioedema (HAE) Attack Rates with Berotralstat Over 24 Months: Results from the Phase
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher? 2021/06/29 11:31:00 The Motley Fool
There''s more than one opportunity for it to do so.
Evercore ISI Stick to Their Buy Rating for Biocryst Pharmaceuticals By Investing.com 2021/04/22 12:08:12 Investing.com
Evercore ISI Stick to Their Buy Rating for Biocryst Pharmaceuticals
BioCryst Technical Levels To Watch 2021/03/22 17:27:43 Benzinga
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX ) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an inadequate response to C5 inhibitors. The stock was down 7.3% at $12.27 at last check. BioCryst has a market cap of $2.25 billion and a public float of 175 million shares. BioCryst Short Term Chart Analysis: Above, the 5-minute chart on BioCryst shows the stock has built higher lows into a resistance … Full story available on Benzinga.com
Hereditary Angioedema Market to Demonstrates a Spectacular Growth with CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies 2021/03/18 06:37:38 OpenPR
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The
The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs 2021/03/12 12:36:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11) Affimed N.V. (NASDAQ: AFMD ) AngioDynamics, Inc. (NASDAQ: ANGO ) Apyx Medical Corporation (NASDAQ: APYX ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) BioAtla, Inc. (NASDAQ: BCAB ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Entera Bio Ltd. (NASDAQ: ENTX ) ( announced positive Phase 2 biomarker data for osteoarthritis drug) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Inari Medical, Inc. (NASDAQ: NARI ) Jounce Therapeutics, Inc. (NASDAQ: JNCE ) Longeveron Inc. (NASDAQ: LGVN ) (announced FDA granting expanded access approval for its investigational cell therapy Lomecel-B to a pediatric patient with hypoplastic left heart syndrome) Magenta Therapeutics, Inc. (NASDAQ: MGTA ) Nuvation Bio Inc. (NASDAQ: NUVB )(announced orphan drug designation for NUV-422 in treating malignant gliomas) Renalytix AI plc (NASDAQ: RNLX ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Surmodics, Inc. (NASDAQ: SRDX ) Verrica Pharmaceuticals Inc. (NASDAQ: VRCA ) Down In The Dumps None of the NYSE- and Nasdaq-listed biotech/diagnostic shares hit 52-week lows Thursday.